The most important event in Q1 2019 was the divestment of the OTC business, providing a capital gain of SEK 556m and this is the main reason for the strong result and cash flow in the quarter. The MOB-015 studies are progressing, and we expect top-line results of the US trial in Q4 2019. We also expect Moberg to distribute SEK 43-45 to its shareholders in H2 2019.